COMPASS Pathways (NASDAQ:CMPS) Given “Outperform” Rating at Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of COMPASS Pathways (NASDAQ:CMPS) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $18.00 target price on the stock.

CMPS has been the topic of several other research reports. HC Wainwright cut their price objective on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Maxim Group cut their price target on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $33.60.

COMPASS Pathways Stock Performance

CMPS stock opened at $3.45 on Wednesday. The firm has a 50-day moving average price of $4.38 and a 200-day moving average price of $5.91. COMPASS Pathways has a 12 month low of $3.16 and a 12 month high of $12.75. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.04. During the same quarter in the prior year, the company posted ($0.67) earnings per share. Research analysts expect that COMPASS Pathways will post -2.33 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CMPS. Logos Global Management LP increased its stake in shares of COMPASS Pathways by 349.3% in the second quarter. Logos Global Management LP now owns 1,159,030 shares of the company’s stock valued at $7,001,000 after buying an additional 901,050 shares during the period. Sio Capital Management LLC boosted its holdings in COMPASS Pathways by 211.7% in the third quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock valued at $5,762,000 after acquiring an additional 621,222 shares during the last quarter. Acuta Capital Partners LLC acquired a new stake in COMPASS Pathways during the 3rd quarter valued at approximately $2,435,000. Walleye Capital LLC acquired a new stake in COMPASS Pathways during the 3rd quarter valued at approximately $2,126,000. Finally, Polar Asset Management Partners Inc. raised its holdings in COMPASS Pathways by 83.3% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock worth $3,576,000 after purchasing an additional 258,000 shares during the last quarter. 46.19% of the stock is owned by institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.